<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Nat Prod</journal-id><journal-id journal-id-type="iso-abbrev">J. Nat. Prod</journal-id><journal-id journal-id-type="publisher-id">np</journal-id><journal-id journal-id-type="coden">jnprdf</journal-id><journal-title-group><journal-title>Journal of Natural Products</journal-title></journal-title-group><issn pub-type="ppub">0163-3864</issn><issn pub-type="epub">1520-6025</issn><publisher><publisher-name>American Chemical
Society and American
Society of Pharmacognosy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24576195</article-id><article-id pub-id-type="pmc">PMC4000582</article-id><article-id pub-id-type="doi">10.1021/np4009865</article-id><article-categories><subj-group><subject>Article</subject></subj-group></article-categories><title-group><article-title>Total Synthesis
of the Lipid Mediator PD1<sub>n-3&#x000a0;DPA</sub>: Configurational
Assignments and Anti-inflammatory and Pro-resolving
Actions</article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><name><surname>Aursnes</surname><given-names>Marius</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath2"><name><surname>Tungen</surname><given-names>J&#x000f8;rn
E.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath3"><name><surname>Vik</surname><given-names>Anders</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath4"><name><surname>Colas</surname><given-names>Romain</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath5"><name><surname>Cheng</surname><given-names>Chien-Yee C.</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath6"><name><surname>Dalli</surname><given-names>Jesmond</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath7"><name><surname>Serhan</surname><given-names>Charles N.</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath8"><name><surname>Hansen</surname><given-names>Trond V.</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref><xref rid="notes-3" ref-type="notes">&#x000a7;</xref></contrib><aff id="aff1"><label>&#x02020;</label>Department
of Pharmaceutical Chemistry, School of Pharmacy, <institution>University of Oslo</institution>, PO Box 1068, Blindern, N-0316 Oslo, <country>Norway</country></aff><aff id="aff2"><label>&#x02021;</label>Center
for Experimental Therapeutics and Reperfusion Injury, Department of
Anesthesiology, Perioperative and Pain Medicine, <institution>Harvard Institutes of Medicine, Brigham and Women&#x02019;s Hospital
and Harvard Medical School</institution>, Boston, Massachusetts 02115, <country>United States</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>E-mail: <email>t.v.hansen@farmasi.uio.no</email>.</corresp></author-notes><pub-date pub-type="pmc-release"><day>27</day><month>02</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>27</day><month>02</month><year>2014</year></pub-date><pub-date pub-type="ppub"><day>25</day><month>04</month><year>2014</year></pub-date><volume>77</volume><issue>4</issue><fpage>910</fpage><lpage>916</lpage><history><date date-type="received"><day>27</day><month>11</month><year>2013</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 American
Chemical Society and American Society of Pharmacognosy</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>American
Chemical Society and American Society of Pharmacognosy</copyright-holder></permissions><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="np-2013-009865_0007" id="ab-d31e220"/></p><p>The polyunsaturated lipid mediator
PD1<sub>n-3&#x000a0;DPA</sub> (<bold>5</bold>) was recently isolated
from self-resolving inflammatory
exudates of <bold>5</bold> and human macrophages. Herein, the first
total synthesis of PD1<sub>n-3&#x000a0;DPA</sub> (<bold>5</bold>) is reported in 10 steps and 9% overall yield. These efforts, together
with NMR data of its methyl ester <bold>6</bold>, confirmed the structure
of <bold>5</bold> to be (7<italic>Z</italic>,10<italic>R</italic>,11<italic>E</italic>,13<italic>E</italic>,15<italic>Z</italic>,17<italic>S</italic>,19<italic>Z</italic>)-10,17-dihydroxydocosa-7,11,13,15,19-pentaenoic
acid. The proposed biosynthetic pathway, with the involvement of an
epoxide intermediate, was supported by results from trapping experiments.
In addition, LC-MS/MS data of the free acid <bold>5</bold>, obtained
from hydrolysis of the synthetic methyl ester <bold>6</bold>, matched
data for the endogenously produced biological material. The natural
product PD1<sub>n-3&#x000a0;DPA</sub> (<bold>5</bold>) demonstrated
potent anti-inflammatory properties together with pro-resolving actions
stimulating human macrophage phagocytosis and efferocytosis. These
results contribute new knowledge on the n-3 DPA structure&#x02013;function
of the growing numbers of specialized pro-resolving lipid mediators
and pathways.</p></abstract><funding-group><funding-statement><funding-source>National Institutes of Health, United States</funding-source></funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>np4009865</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>np-2013-009865</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><p id="sec1">Resolution
of inflammation is
necessary to re-establish homeostasis after injury or infection.<sup><xref ref-type="bibr" rid="ref1">1</xref>&#x02212;<xref ref-type="bibr" rid="ref3">3</xref></sup> Excessive inflammatory responses that fail to undergo resolution
may lead to chronic inflammation associated with many diseases, such
as asthma, atherosclerosis, autoimmune diseases, cancer, and neuropathological
disorders, including Alzheimer&#x02019;s and Parkinson&#x02019;s diseases.<sup><xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref2">2</xref></sup> Hence, over the last century, inflammation has been the topic of
numerous studies at the molecular and cellular level.<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> As of today, several chemical mediators have been identified
that can initiate, modulate, and reduce acute inflammation and stimulate
resolution.<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> Continued efforts have established
that the return to homeostasis, catabasis,<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> is mediated by active biosynthesis and termination programs orchestrated
by novel families of natural products coined specialized pro-resolving
mediators (SPMs).<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> The SPMs are derived
from polyunsaturated fatty acids (PUFAs) during the resolution phase
of acute inflammation.<sup><xref ref-type="bibr" rid="ref6">6</xref>,<xref ref-type="bibr" rid="ref7">7</xref></sup> These efforts have provided the
fundamentals for the molecular understanding of the resolution of
many inflammatory diseases.<sup><xref ref-type="bibr" rid="ref7">7</xref></sup></p><p>Recent
studies have identified several novel SPMs biosynthesized
from the dietary n-3 PUFAs eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA). These novel di- and trihydroxy-containing PUFA-derived
lipid mediators are termed resolvins, protectins, and maresins. Resolvin
E1 (<bold>1</bold>) is produced from EPA,<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> while resolvin D1 (<bold>2</bold>),<sup><xref ref-type="bibr" rid="ref9">9</xref>,<xref ref-type="bibr" rid="ref10">10</xref></sup> protectin
D1 (PD1, <bold>3</bold>),<sup><xref ref-type="bibr" rid="ref9">9</xref>&#x02212;<xref ref-type="bibr" rid="ref12">12</xref></sup> also known as neuroprotectin D1 (NPD1) when produced
in neural systems,<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> and maresin 1 (<bold>4</bold>)<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> are produced from DHA.<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="np-2013-009865_0008" id="fx1" position="float"/></p><p>These mediators are examples of SPMs structurally elucidated
within
the past decade showing potent in vivo anti-inflammatory and pro-resolving
activities resulting in catabasis.<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> It
is now well established that EPA and DHA are substrates for the enzymatic
formation of the aforementioned SPMs. The naturally occurring compounds <bold>1</bold>&#x02013;<bold>4</bold> have been the subject of many pharmacological
studies for the development of potential new anti-inflammatory drugs,<sup><xref ref-type="bibr" rid="ref14">14</xref>,<xref ref-type="bibr" rid="ref15">15</xref></sup> and some have already been the subject of clinical trials.<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> These autacoids exhibit stereochemically selective
modes of actions, reflecting their routes of biosynthesis.<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> In light of this, we became interested in investigations
using other n-3 PUFAs than EPA and DHA as potential substrates for
the endogenous formation of novel SPMs. In humans, genome-wide association
studies demonstrate that elevation in circulating levels of n-3 docosapentaenoic
acid (n-3 DPA), or (7<italic>Z</italic>,10<italic>Z</italic>,13<italic>Z</italic>,16<italic>Z</italic>,19<italic>Z</italic>)-docosapentaenoic
acid, with a concomitant decrease in DHA levels, are associated with
single nucleotide polymorphisms in the gene encoding for the fatty
acid elongase 2 (ELOVL2).<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> The levels
of circulating n-3 DPA do not appear to be directly associated with
dietary intake of PUFAs.<sup><xref ref-type="bibr" rid="ref17">17</xref>,<xref ref-type="bibr" rid="ref18">18</xref></sup> Recently Dalli et al.
reported that n-3 DPA was converted to novel SPMs by both human and
murine leukocytes.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> One of the novel products
identified was assigned the structure (7<italic>Z</italic>,11<italic>E</italic>,13<italic>E</italic>,15<italic>Z</italic>,17<italic>S</italic>,19<italic>Z</italic>)-10,17-dihydroxydocosa-7,11,13,15,19-pentaenoic
acid and denoted PD1<sub>n-3&#x000a0;DPA</sub> (<bold>5</bold>), given its relation to PD1 (<bold>3</bold>)<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> (Figure <xref rid="fig1" ref-type="fig">1</xref>).</p><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Proposed biosynthesis
of PD1<sub>n-3&#x000a0;DPA</sub> (<bold>5</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="np-2013-009865_0002" id="gr3" position="float"/></fig><p>The only apparent structural difference between
DHA and n-3 DPA
is the absence of a <italic>cis</italic>-double bond at the C-4 position.
This difference is proposed to confer unique biophysical properties
relevant for biological functions.<sup><xref ref-type="bibr" rid="ref21">21</xref></sup> With
the aim of providing multimilligram quantities for biological studies,
the synthesis of n-3 DPA was achieved.<sup><xref ref-type="bibr" rid="ref22">22</xref></sup></p><p>The initial structural assignment of the n-3 DPA-derived compound
PD1<sub>n-3&#x000a0;DPA</sub> (<bold>5</bold>) was based on biosynthetic
results with human polymorphonuclear leukocytes (PMN) followed by
chromatographic purification employing LC-MS/MS fragmentation. Moreover,
the natural product <bold>5</bold> exhibited identical chromatographic
properties with RvD5<sub>n-3&#x000a0;DPA</sub>, or (7<italic>S</italic>,8<italic>E</italic>,10<italic>Z</italic>,13<italic>Z</italic>,15<italic>E</italic>,17<italic>S</italic>,19<italic>Z</italic>)-7,17-dihydroxydocosa-8,10,13,15,19-pentaenoic
acid, produced under the same experimental conditions.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> Therefore, the full stereochemical assignment
of the double-bond geometry in the conjugated triene system as well
as the absolute configuration of the C-10 group remained to be established.
Also, the assignment of the <italic>S</italic>-configuration on carbon
atom 17 was based on biosynthetic considerations. Hence, total synthesis
became necessary for establishing the complete configurational assignment
of <bold>5</bold>, as has been necessary for the novel SPMs of interest,
but also due to the pico- to nanogram amounts produced in vivo.<sup><xref ref-type="bibr" rid="ref15">15</xref>,<xref ref-type="bibr" rid="ref19">19</xref></sup> In addition, the biological actions of <bold>5</bold> remained to
be confirmed. Herein, we report the synthesis and the elucidation
of the absolute configuration of SPM <bold>5</bold> based on matching
data from both LC-MS/MS and GC/MS analyses of synthetic and endogenous
materials, as well as 1D- and 2D-NMR spectroscopic data of its methyl
ester <bold>6</bold>. The novel bioactions of <bold>5</bold> are also
reported.</p><sec id="sec2"><title>Results and Discussion</title><p>The synthesis of PD1<sub>n-3&#x000a0;DPA</sub> (<bold>5</bold>) commenced with the preparation of the Wittig salt <bold>7</bold> in four steps from cycloheptanone (<bold>8</bold>). First,
a Baeyer&#x02013;Villiger
oxidation<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> of <bold>8</bold> yielded lactone <bold>9</bold>, which was reacted with MeOH and catalytic amounts of H<sub>2</sub>SO<sub>4</sub> to produce methyl-7-hydroxyheptanoate (<bold>10</bold>). The alcohol functionality in <bold>10</bold> was converted
into the corresponding iodide <bold>11</bold>. Reacting triphenylphosphine
with <bold>11</bold> afforded the desired Wittig salt <bold>7</bold> in 62% yield from <bold>8</bold> (Scheme <xref rid="sch1" ref-type="scheme">1</xref>). Then (3<italic>R</italic>,4<italic>E</italic>,6<italic>E</italic>)-7-bromo-3-((<italic>tert</italic>-butyldimethylsilyl)oxy)hepta-4,6-dienal
(<bold>12</bold>) was prepared as previously reported from salt <bold>13</bold>.<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> Aldehyde <bold>12</bold> was
reacted with the ylide of <bold>7</bold>, the latter obtained after
reaction with NaHMDS in THF at &#x02212;78 &#x000b0;C, in a <italic>Z</italic>-selective Wittig reaction. After purification using silica gel chromatography,
pure vinylic bromide ester <bold>14</bold> was obtained in 54% yield
(Scheme <xref rid="sch1" ref-type="scheme">1</xref>). The stereoisomeric purity of <bold>14</bold> was determined by HPLC and <sup>1</sup>H NMR analyses (<xref rid="notes-2" ref-type="notes">Supporting Information</xref>).</p><fig id="sch1" position="float"><label>Scheme 1</label><caption><title>Synthesis of Wittig
Salt <bold>7</bold> and Intermediate <bold>14</bold></title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="np-2013-009865_0005" id="gr1" position="float"/></fig><p>The alkyne <bold>15</bold> was synthesized essentially
as previously
reported from 1-butyne (<bold>16</bold>) and (<italic>R</italic>)-THP
glycidol (<bold>17</bold>).<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> Then vinylic
bromide ester <bold>14</bold> and alkyne <bold>15</bold> were reacted
in a Sonogashira reaction<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> at ambient
temperature in the presence of catalytic Pd(PPh<sub>3</sub>)<sub>4</sub> and CuI with diethyl amine as solvent. This afforded the bis-TBS-protected
methyl ester <bold>18</bold> in 92% yield. Deprotection of the two
TBS groups in <bold>18</bold> with five equivalents of TBAF in THF
at 0 &#x000b0;C gave an 85% yield of the diol <bold>19</bold>.<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> The internal alkyne in <bold>19</bold> was reduced
to the <italic>Z</italic>,<italic>E</italic>,<italic>E</italic>,<italic>Z</italic>,Z-pentaene ester <bold>6</bold> in 50% yield using a modified
Lindlar hydrogenation reaction<sup><xref ref-type="bibr" rid="ref28">28</xref></sup> with high
stereoselectivity, as only one diastereomer was detected by HPLC and <sup>1</sup>H NMR analyses. Finally, hydrolysis of the methyl ester <bold>6</bold> at 0 &#x000b0;C with dilute aqueous LiOH in MeOH followed by
mild acidic workup with aqueous NaH<sub>2</sub>PO<sub>4</sub><sup><xref ref-type="bibr" rid="ref29">29</xref></sup> resulted in a 71% yield of PD1<sub>n-3&#x000a0;DPA</sub> (<bold>5</bold>) after purification by column chromatography (Scheme <xref rid="sch2" ref-type="scheme">2</xref>).</p><fig id="sch2" position="float"><label>Scheme 2</label><caption><title>Final Steps of the Synthesis of PD1<sub>n-3&#x000a0;DPA</sub> (<bold>5</bold>)</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="np-2013-009865_0006" id="gr2" position="float"/></fig><p>The assignment of the <italic>Z-</italic> or <italic>E</italic>-geometry for each of the double bonds was achieved by two-dimensional
NMR spectroscopy, with MeOH-<italic>d</italic><sub>4</sub> as the
solvent and internal standard. These experiments revealed the connectivity
between adjacent olefinic hydrogens (H-7/H-8, H-11/H-16, and H-19/H-20),
which in connection with the data from the HMBC spectra permitted
the assignment of all olefinic hydrogens. In particular, the signals
at 5.74 (dd, 1H, <italic>J</italic> = 14.4 Hz) and 6.07 ppm (t, 1H, <italic>J</italic> = 11.0 Hz) were diagnostic for an <italic>E</italic>-
and <italic>Z</italic>-double bond, respectively. The COSY spectrum
was used for assigning vicinal signals for both of the two isolated <italic>Z</italic>-olefins and the <italic>E</italic>,<italic>E</italic>,<italic>Z</italic>-triene moiety. Moreover, two signals from the hydrogen
atoms attached to the carbinol carbon atoms were observed as expected
with signals at 4.12 (m, 1H) and 4.56 ppm (dt, 1H, <italic>J</italic> = 8.9, 6.8 Hz). The HSQC spectrum was used for assigning the signals
from the methylene carbons at 36.36 and 36.38 ppm, next to the C-19/C-20
and the C-7/C-8 <italic>Z</italic>-double bonds, respectively. The
data from the <sup>1</sup>H and <sup>13</sup>C NMR spectra, in combination
with the COSY and the HMBC spectra, allowed the structural assignment
of the rest of the molecule (Table <xref rid="tbl1" ref-type="other">1</xref>).</p><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><title>Compilation of <sup>1</sup>H and <sup>13</sup>C NMR
Data of the Methyl Ester <bold>6</bold><xref rid="t1fn1" ref-type="table-fn">a</xref></title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="char" char="."/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">position</th><th style="border:none;" align="center" char=".">&#x003b4;<sub>C</sub>, mult.<xref rid="t1fn2" ref-type="table-fn">b</xref></th><th style="border:none;" align="center">&#x003b4;<sub>H</sub>, mult. (<italic>J</italic> in Hz)<xref rid="t1fn3" ref-type="table-fn">c</xref></th><th style="border:none;" align="center">HMBC<xref rid="t1fn4" ref-type="table-fn">d</xref></th><th style="border:none;" align="center">COSY</th></tr></thead><tbody><tr><td style="border:none;" align="left">1</td><td style="border:none;" align="char" char=".">175.9,&#x000a0;C</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td></tr><tr><td style="border:none;" align="left">2</td><td style="border:none;" align="char" char=".">34.8, CH<sub>2</sub></td><td style="border:none;" align="left">2.31,&#x000a0;m</td><td style="border:none;" align="left">1, 3, 4</td><td style="border:none;" align="left">3</td></tr><tr><td style="border:none;" align="left">3</td><td style="border:none;" align="char" char=".">25.9, CH<sub>2</sub></td><td style="border:none;" align="left">1.60, quint (7.3)</td><td style="border:none;" align="left">1,&#x000a0;2,&#x000a0;4,&#x000a0;5</td><td style="border:none;" align="left">2,
4</td></tr><tr><td style="border:none;" align="left">4</td><td style="border:none;" align="char" char=".">29.8, CH<sub>2</sub></td><td style="border:none;" align="left">1.33, m</td><td style="border:none;" align="left">2, 3, 5, 6</td><td style="border:none;" align="left">3, 5</td></tr><tr><td style="border:none;" align="left">5</td><td style="border:none;" align="char" char=".">30.3, CH<sub>2</sub></td><td style="border:none;" align="left">1.37,
m</td><td style="border:none;" align="left">3, 4, 6, 7</td><td style="border:none;" align="left">4,&#x000a0;6</td></tr><tr><td style="border:none;" align="left">6</td><td style="border:none;" align="char" char=".">28.2, CH<sub>2</sub></td><td style="border:none;" align="left">2.04, m</td><td style="border:none;" align="left">4, 5, 7, 8</td><td style="border:none;" align="left">5, 7</td></tr><tr><td style="border:none;" align="left">7</td><td style="border:none;" align="char" char=".">132.8, CH</td><td style="border:none;" align="left">5.47, m</td><td style="border:none;" align="left">5, 6, 9</td><td style="border:none;" align="left">6, 8</td></tr><tr><td style="border:none;" align="left">8</td><td style="border:none;" align="char" char=".">126.2, CH</td><td style="border:none;" align="left">5.40, m</td><td style="border:none;" align="left">6, 9, 10</td><td style="border:none;" align="left">7, 9</td></tr><tr><td style="border:none;" align="left">9</td><td style="border:none;" align="char" char=".">36.4, CH<sub>2</sub></td><td style="border:none;" align="left">2.26 + 2.32,&#x000a0;m</td><td style="border:none;" align="left">7, 8, 10, 11</td><td style="border:none;" align="left">8, 10</td></tr><tr><td style="border:none;" align="left">10</td><td style="border:none;" align="char" char=".">73.1, CH</td><td style="border:none;" align="left">4.12, m</td><td style="border:none;" align="left">8, 9, 11, 12</td><td style="border:none;" align="left">9, 11</td></tr><tr><td style="border:none;" align="left">11</td><td style="border:none;" align="char" char=".">138.0, CH</td><td style="border:none;" align="left">5.74, dd (14.4, 6.7)</td><td style="border:none;" align="left">9, 10, 13</td><td style="border:none;" align="left">10, 12</td></tr><tr><td style="border:none;" align="left">12</td><td style="border:none;" align="char" char=".">131.3, CH</td><td style="border:none;" align="left">6.26, m</td><td style="border:none;" align="left">10, 11, 13, 14</td><td style="border:none;" align="left">11, 13</td></tr><tr><td style="border:none;" align="left">13</td><td style="border:none;" align="char" char=".">134.9, CH</td><td style="border:none;" align="left">6.24, m</td><td style="border:none;" align="left">11, 12, 15</td><td style="border:none;" align="left">12, 14</td></tr><tr><td style="border:none;" align="left">14</td><td style="border:none;" align="char" char=".">128.9, CH</td><td style="border:none;" align="left">6.52, dd
(13.8, 11.2)</td><td style="border:none;" align="left">12, 13, 15, 16</td><td style="border:none;" align="left">13, 15</td></tr><tr><td style="border:none;" align="left">15</td><td style="border:none;" align="char" char=".">130.5, CH</td><td style="border:none;" align="left">6.07, t</td><td style="border:none;" align="left">13, 14, 16, 17</td><td style="border:none;" align="left">14, 16</td></tr><tr><td style="border:none;" align="left">16</td><td style="border:none;" align="char" char=".">134.8, CH</td><td style="border:none;" align="left">5.38, m</td><td style="border:none;" align="left">14,
18</td><td style="border:none;" align="left">15, 17</td></tr><tr><td style="border:none;" align="left">17</td><td style="border:none;" align="char" char=".">68.6, CH</td><td style="border:none;" align="left">4.56, dt (8.9, 6.8)</td><td style="border:none;" align="left">15, 16,
18, 19</td><td style="border:none;" align="left">16, 18</td></tr><tr><td style="border:none;" align="left">18</td><td style="border:none;" align="char" char=".">36.4, CH<sub>2</sub></td><td style="border:none;" align="left">2.36 + 2.21,&#x000a0;m</td><td style="border:none;" align="left">16, 17, 19, 20</td><td style="border:none;" align="left">17, 19</td></tr><tr><td style="border:none;" align="left">19</td><td style="border:none;" align="char" char=".">125.3, CH</td><td style="border:none;" align="left">5.34, m</td><td style="border:none;" align="left">17, 18, 20, 21</td><td style="border:none;" align="left">18, 20</td></tr><tr><td style="border:none;" align="left">20</td><td style="border:none;" align="char" char=".">134.7, CH</td><td style="border:none;" align="left">5.45, m</td><td style="border:none;" align="left">18, 19, 21, 22</td><td style="border:none;" align="left">19, 21</td></tr><tr><td style="border:none;" align="left">21</td><td style="border:none;" align="char" char=".">21.7, CH<sub>2</sub></td><td style="border:none;" align="left">2.07, m</td><td style="border:none;" align="left">19, 20, 22</td><td style="border:none;" align="left">20, 22</td></tr><tr><td style="border:none;" align="left">22</td><td style="border:none;" align="char" char=".">14.6, CH<sub>3</sub></td><td style="border:none;" align="left">0.97, t (7.5)</td><td style="border:none;" align="left">20, 21</td><td style="border:none;" align="left">21</td></tr><tr><td style="border:none;" align="left">23</td><td style="border:none;" align="char" char=".">52.0, CH<sub>3</sub></td><td style="border:none;" align="left">3.65, s</td><td style="border:none;" align="left">1</td><td style="border:none;" align="left">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="t1fn1"><label>a</label><p>MeOH-<italic>d</italic><sub>4</sub> was used as solvent. See Figure <xref rid="fig1" ref-type="fig">1</xref> for atom
labeling.</p></fn><fn id="t1fn2"><label>b</label><p>Measured at 125
MHz.</p></fn><fn id="t1fn3"><label>c</label><p>Measured at 500 MHz.</p></fn><fn id="t1fn4"><label>d</label><p>HMBC correlations are from
proton(s)
stated to the indicated carbon(s). The ppm values listed above for
&#x003b4;<sub>H</sub> were assigned using the center of the COSY and
HSQC peak intensities.</p></fn></table-wrap-foot></table-wrap><p>UV
spectra for both synthetic and endogenously produced PD1<sub>n-3&#x000a0;DPA</sub> (<bold>5</bold>) were compared. For synthetic <bold>5</bold>, &#x003bb;<sub>max</sub><sup>MeOH</sup> absorbances were observed
at 262, 271, and 282 nm; all in excellent agreement with the endogenous
product<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> (261, 271, 282 nm, &#x003bb;<sub>max</sub><sup>MeOH</sup>), as well as with literature values.<sup><xref ref-type="bibr" rid="ref30">30</xref></sup> Synthetic <bold>5</bold> was treated with excess
diazomethane followed by <italic>N</italic>,<italic>O</italic>-bis(trimethylsilyl)trifluoroacetamide
(BSTFA) to produce the bis-TMS ether of methyl ester <bold>6</bold>, which was subjected to GC/MS (<xref rid="notes-2" ref-type="notes">Supporting Information</xref>, Figure S-25). The following characteristic <italic>m</italic>/<italic>z</italic> values were observed: 520 = M, 505 = M &#x02013; CH<sub>3</sub>, 489 = M &#x02013; OCH<sub>3</sub>, 430 = M &#x02013; OTMS,
340 = M &#x02013; 2&#x000d7;OTMS, and 73 = TMS.</p><p>Experiments supporting
the proposed biosynthetic pathway in Figure <xref rid="fig2" ref-type="fig">2</xref> were then performed. Soybean lipoxygenase was incubated
with n-3 DPA in borate buffer (pH = 8.0) at ambient temperature essentially
as described.<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> Excess acidic MeOH was added
to quench the reaction and promote opening of the epoxide. Then the
product mixture was assessed by lipid mediator metabololipidomics.<sup><xref ref-type="bibr" rid="ref31">31</xref>,<xref ref-type="bibr" rid="ref32">32</xref></sup> From the MS/MS fragmentation patterns of the formed products, four
structures were assigned (<xref rid="notes-2" ref-type="notes">Figure S-26</xref>).
These results render support for the proposed biosynthetic pathway<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> as depicted in Figure <xref rid="fig2" ref-type="fig">2</xref>, involving an acid-catalyzed ring-opening of the 16,17-epoxyPD<sub>n-3&#x000a0;DPA</sub>. In addition, these observations are in
accordance with the reaction pathway reported by Corey and Mehrotra<sup><xref ref-type="bibr" rid="ref33">33</xref></sup> as well as enzyme-catalyzed mechanisms in the
biosynthesis of other pro-resolving mediators.<sup><xref ref-type="bibr" rid="ref34">34</xref></sup></p><p>In order to determine whether synthetic <bold>5</bold> matched
endogenous PD1<sub>n-3&#x000a0;DPA</sub> (<bold>5</bold>), authentic <bold>5</bold> from murine self-resolving exudates as well as human macrophages
was employed.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> Figure <xref rid="fig2" ref-type="fig">2</xref>A shows human macrophage PD1<sub>n-3&#x000a0;DPA</sub> (<bold>5</bold>) from n-3 DPA with a retention time (<italic>t</italic><sub>R</sub>) of 12.4 min, together with its natural isomers. Figure <xref rid="fig2" ref-type="fig">2</xref>B depicts endogenous PD1<sub>n-3&#x000a0;DPA</sub> (<bold>5</bold>) from mouse peritoneal exudates that also displayed <italic>t</italic><sub>R</sub> = 12.4 min. This is shown together with its
natural isomers produced in mouse peritoneal exudates. The chromatographic
behavior of synthetic <bold>5</bold> (<italic>t</italic><sub>R</sub> = 12.4 min), obtained from hydrolysis of synthetic methyl ester <bold>6</bold>, is shown in Figure <xref rid="fig2" ref-type="fig">2</xref>C. Figure <xref rid="fig2" ref-type="fig">2</xref>D reports the co-injection of synthetic and endogenously
obtained material added at essentially equal amounts. Altogether,
Figure <xref rid="fig2" ref-type="fig">2</xref> demonstrates that synthetic <bold>5</bold> coelutes with endogenously obtained <bold>5</bold>. In addition,
the MS/MS spectra for both natural and synthetic <bold>5</bold> were
essentially identical (<xref rid="notes-2" ref-type="notes">Figure S-24</xref>).</p><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Endogenous
PD1<sub>n-3&#x000a0;DPA</sub> (<bold>5</bold>) from
human macrophages and resolving inflammatory exudates match synthetic
material. MRM chromatograms for selected ion pair <italic>m</italic>/<italic>z</italic> 361&#x02013;183 depicting (A) PD1<sub>n-3&#x000a0;DPA</sub> (<bold>5</bold>) from human macrophages (5 &#x000d7; 10<sup>7</sup> cells/mL) incubated with 0.1 mg of opsonized zymosan and n-3 DPA
(1 &#x003bc;M, 37 &#x000b0;C, 30 min, DPBS<sup>+/+</sup>, pH = 7.45). Results
are representative of <italic>n</italic> = 3 human macrophage preparations.
(B) Endogenous PD1<sub>n-3&#x000a0;DPA</sub> (<bold>5</bold>)
obtained from mice injected with zymosan (1 mg/mouse) and exudates
collected at 4 h. Results are representative of <italic>n</italic> = 4 mice exudates. (C) Synthetic material (inset: characteristic
UV-absorption spectrum, &#x003bb;<sub>max</sub><sup>MeOH</sup> &#x000b1;
1 nm). (D) Co-injection of resolving exudate endogenous PD1<sub>n-3&#x000a0;DPA</sub> (<bold>5</bold>) with synthetic material. Results are representative
of <italic>n</italic> = 4.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="np-2013-009865_0003" id="gr4" position="float"/></fig><p>Having established that the physical properties of synthetic <bold>5</bold> matched those of endogenous <bold>5</bold>, we next required
the confirmation of its anti-inflammatory and pro-resolving actions.
Administration of synthetic <bold>5</bold> at a dose as low as 10
ng per mouse significantly reduced neutrophil recruitment during peritonitis,
giving a significant reduction in the number of neutrophils recovered
from peritoneal exudates following zymosan (1 mg/mouse) challenge
determined by light microscopy and flow cytometry (Figure <xref rid="fig3" ref-type="fig">3</xref>A). These actions were comparable to those displayed
by the potent DHA-derived pro-resolving mediator protectin D1 (<bold>3</bold>).<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> Human macrophage phagocytosis
and efferocytosis (clearance of apoptotic neutrophils) are key processes
in the resolution of inflammation<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> and
defining actions of SPMs.<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> The ability
of synthetic <bold>5</bold> in this system to stimulate human macrophage
phagocytosis and efferocytosis was investigated.<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> Incubation of synthetic <bold>5</bold> with human macrophages
and increasing concentrations of <bold>5</bold> led to an increase
in macrophage phagocytosis of both fluorescence-labeled yeast cell
wall particles (zymosan) and apoptotic neutrophils. These actions
were shared with the DHA-derived protectin D1 (<bold>3</bold>) (Figure <xref rid="fig3" ref-type="fig">3</xref>B). In addition, PD1<sub>n-3&#x000a0;DPA</sub> (<bold>5</bold>) displayed potent efferocytosis effects against
apoptotic human neutrophils (Figure <xref rid="fig3" ref-type="fig">3</xref>C). PD1<sub>n-3&#x000a0;DPA</sub> stimulated proresolving actions with macrophages
at picomolar concentrations and appeared to give a trend toward a
bell-shaped dose&#x02013;response with these isolated human cells.
These findings demonstrate that <bold>5</bold> displayed both potent
anti-inflammatory and pro-resolving actions, confirming the potent
immunoresolvent properties of PD1<sub>n-3&#x000a0;DPA</sub> (<bold>5</bold>).</p><fig id="fig3" position="float"><label>Figure 3</label><caption><p>PD1<sub>n-3&#x000a0;DPA</sub> (<bold>5</bold>) displays potent
anti-inflammatory and pro-resolving actions. PD1<sub>n-3&#x000a0;DPA,</sub> (<bold>5</bold>), PD1 (<bold>3</bold>), or vehicle (saline containing
0.01% EtOH) were administered iv 5 min prior to ip administration
of zymosan (1 mg). Exudates were collected at 4 h, and the number
of infiltrated neutrophils was determined by flow cytometry (top right
inset) and light microscopy. Results are mean &#x000b1; SEM. <italic>n</italic> = 4 mice per treatment (**<italic>p</italic> &#x0003c; 0.01
vs vehicle group). (B, C) Macrophages were incubated with vehicle
(0.1% EtOH in PBS), PD1<sub>n-3&#x000a0;DPA</sub> (<bold>5</bold>) (100 nM to 10 pM), or PD1 (<bold>3</bold>) (100 nM to 10 pM; 15
min, 37 &#x000b0;C, pH = 7.45) prior to addition of (B) fluorescently
labeled zymosan (1:10 macrophages to zymosan) or (C) fluorescently
labeled apoptotic human neutrophils. After 60 min (37 &#x000b0;C, pH
= 7.45), the incubation was stopped, extracellular fluorescence quenched
using trypan blue, and phagocytosis assessed using a SpectraMax M3
plate reader. Results are mean &#x000b1; SEM. <italic>n</italic> = 4
macrophage preparations (*<italic>p</italic> &#x0003c; 0.05 vs PBS-incubated
macrophages).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="np-2013-009865_0004" id="gr5" position="float"/></fig><p>The complete structure
elucidation and a stereocontrolled total
synthesis of PD1<sub>n-3&#x000a0;DPA</sub> have been reported.
These efforts unambiguously confirmed the structure of PD1<sub>n-3&#x000a0;DPA</sub> (<bold>5</bold>) to be (7<italic>Z</italic>,10<italic>R</italic>,11<italic>E</italic>,13<italic>E</italic>,15<italic>Z</italic>,17<italic>S</italic>,19<italic>Z</italic>)-10,17-dihydroxydocosa-7,11,13,15,19-pentaenoic
acid. The synthetic material was matched to that of endogenously produced
PD1<sub>n-3&#x000a0;DPA</sub> (<bold>5</bold>). Compound <bold>5</bold> displayed potent anti-inflammatory and pro-resolving activities
characteristic for members of the SPM class of natural products. The
dihydroxy-polyunsaturated fatty acid <bold>5</bold> is a congener
with the DHA-derived protectin D1 (<bold>3</bold>).<sup><xref ref-type="bibr" rid="ref7">7</xref>&#x02212;<xref ref-type="bibr" rid="ref11">11</xref>,<xref ref-type="bibr" rid="ref20">20</xref></sup> Protectin D1 (<bold>3</bold>) exhibits potent protective activity in vivo in models of
inflammatory diseases<sup><xref ref-type="bibr" rid="ref5">5</xref>,<xref ref-type="bibr" rid="ref20">20</xref></sup> as well as other interesting
biological actions in organ protection<sup><xref ref-type="bibr" rid="ref30">30</xref></sup> and reduces pain.<sup><xref ref-type="bibr" rid="ref35">35</xref></sup> Further biological
evaluations of PD1<sub>n-3&#x000a0;DPA</sub> (<bold>5</bold>)
are ongoing and will be reported separately.</p></sec><sec id="sec3"><title>Experimental
Section</title><sec id="sec3.1"><title>General Experimental Procedures</title><p>Unless stated otherwise,
all commercially available reagents and solvents were used in the
form they were supplied without any further purification. The stated
yields are based on isolated material. Zymosan was purchased from
Sigma-Aldrich. Optical rotations were measured using a 1 mL cell with
a 1.0 dm path length on a Perkin-Elmer 341 polarimeter. The UV/vis
spectra from 190 to 900 nm were recorded using a Biochrom Libra S32PC
spectrometer using quartz cuvettes. IR spectra (4000&#x02013;600 cm<sup>&#x02013;1</sup>) were obtained on a Perkin-Elmer Spectrum BX series
FT-IR spectrophotometer. NMR spectra were recorded on a Bruker DRX500
or a Bruker AVII400 spectrometer at 500 or 400 MHz, respectively,
for <sup>1</sup>H NMR and at 126 or 101 MHz, respectively, for <sup>13</sup>C NMR. Spectra are referenced relative to the central residual
protium solvent resonance in <sup>1</sup>H NMR (CDCl<sub>3</sub> &#x003b4;
= 7.27 and MeOH-<italic>d</italic><sub>4</sub> &#x003b4; = 3.31) and
the central carbon solvent resonance in <sup>13</sup>C NMR (CDCl<sub>3</sub> &#x003b4; = 77.00 ppm and MeOH-<italic>d</italic><sub>4</sub> = &#x003b4; 49.00). Mass spectra were recorded at 70 eV on a Waters
Prospec Q spectrometer using EI, ES, or CI as the method of ionization.
High-resolution mass spectra were recorded on a Waters Prospec Q spectrometer
using EI or ES as the methods of ionization. Thin-layer chromatography
was performed on silica gel 60 F254 aluminum-backed plates fabricated
by Merck. Flash column chromatography was performed on silica gel
60 (40&#x02013;63 &#x003bc;m) produced by Merck. HPLC analyses were performed
on an Agilent Technologies 1200 Series instrument with diode array
detector set at 254 nm and equipped with a C18 stationary phase (Eclipse
XDB-C18 5 &#x003bc;m, 4.6 &#x000d7; 150 mm), applying the conditions stated.
Diastereomeric ratios reported in this paper have not been validated
by calibration.<sup><xref ref-type="bibr" rid="ref36">36</xref></sup></p></sec><sec id="sec3.2"><title>Methyl (10<italic>R</italic>,7<italic>Z</italic>,11<italic>E</italic>,13<italic>E</italic>)-14-Bromo-10-((<italic>tert</italic>-butyldimethylsilyl)oxy)tetradeca-7,11,13-trienoate
(<bold>14</bold>)</title><p>To the Wittig salt <bold>7</bold> (1.67
g, 3.13 mmol, 1.0 equiv) in THF (47 mL) was added NaHMDS (0.6 M in
toluene, 1.0 equiv) at &#x02212;78 &#x000b0;C, and the mixture was stirred
for 60 min at that temperature. Aldehyde <bold>12</bold> was added.
The solution was allowed to warm slowly to room temperature in a dry
ice/acetone bath and stirred for 24 h before it was quenched with
phosphate buffer (45 mL, pH = 7.2). Et<sub>2</sub>O (60 mL) was added,
and the phases were separated. The H<sub>2</sub>O phase was extracted
with Et<sub>2</sub>O (2 &#x000d7; 60 mL) and the combined organic layers
were dried (Na<sub>2</sub>SO<sub>4</sub>), before the solvent was
evaporated. The crude product was purified by column chromatography
on silica (hexanes/EtOAc, 97:3) to afford the title compound <bold>14</bold> as a colorless oil. Yield: 754 mg (54% over two steps).
[&#x003b1;]<sup>20</sup><sub>D</sub> &#x02212;18 (<italic>c</italic> 0.09,
MeOH); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x003b4; 6.68
(dd, <italic>J</italic> = 13.4, 10.9 Hz, 1H), 6.27 (d, <italic>J</italic> = 13.5 Hz, 1H), 6.09 (dd, <italic>J</italic> = 15.2, 10.9 Hz, 1H),
5.71 (dd, <italic>J</italic> = 15.3, 9.6 Hz, 1H), 5.48&#x02013;5.29
(m, 1H), 4.13 (dd, <italic>J</italic> = 6.0, 1.4 Hz, 1H), 3.66 (s,
3H), 2.30 (t, <italic>J</italic> = 7.5 Hz, 2H), 2.28&#x02013;2.17 (m,
2H), 2.05&#x02013;1.95 (m, 2H), 1.62 (p, <italic>J</italic> = 7.4 Hz,
2H), 1.40&#x02013;1.25 (m, 4H), 0.89 (s, 9H), 0.04 (s, 3H), 0.02 (s,
3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) &#x003b4; 174.3,
138.1, 137.2, 131.9, 126.6, 125.2, 108.2, 72.7, 51.6, 36.3, 34.2,
29.4, 29.0, 27.4, 26.0 (3C), 25.0, 18.4, &#x02212;4.4, &#x02212;4.6;
HREIMS <italic>m</italic>/<italic>z</italic> 447.1751 [M <italic>+ </italic>H]<sup>+</sup> (calcd for C<sub>21</sub>H<sub>38</sub><sup>81</sup>BrO<sub>3</sub>Si, 447.1753); TLC (hexanes/EtOAc, 95:5, CAM stain) <italic>R</italic><sub><italic>f</italic></sub> = 0.21; diastereomeric ratio
(&#x0003e;98%) was determined by HPLC analysis (Eclipse XDB-C18, MeOH/H<sub>2</sub>O, 92:8, 1.1 mL/min); <italic>t</italic><sub>r</sub>(minor)
= 8.41 and 8.74 min and <italic>t</italic><sub>r</sub>(major) = 9.30
min.</p></sec><sec id="sec3.3"><title>Methyl (7<italic>Z</italic>,10<italic>R</italic>,11<italic>E</italic>,13<italic>E</italic>,17<italic>S</italic>,19<italic>Z</italic>)-10,17-Bis((<italic>tert</italic>-butyldimethylsilyl)oxy)docosa-7,11,13,19-tetraen-15-ynoate
(<bold>18</bold>)</title><p>To a solution of vinyl bromide <bold>14</bold> (285 mg, 0.64 mmol, 1.0 equiv) in Et<sub>2</sub>NH (1.5 mL) and
benzene (0.6 mL) was added Pd(PPh<sub>3</sub>)<sub>4</sub> (22 mg,
0.019 mmol, 3 mol %), and the reaction was stirred for 45 min in the
dark. CuI (6 mg, 0.032 mmol, 5 mol %) in a minimum amount of Et<sub>2</sub>NH was added, followed by dropwise addition of alkyne <bold>15</bold> (153 mg, 0.64 mmol, 1.0 equiv) in Et<sub>3</sub>N (1.5
mL). After stirring at ambient temperature for 20 h, the reaction
was quenched by saturated NH<sub>4</sub>Cl (15 mL). Et<sub>2</sub>O (15 mL) was added, and the phases were separated. The H<sub>2</sub>O phase was extracted with Et<sub>2</sub>O (2 &#x000d7; 15 mL) and the
combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>),
before the solvent was evaporated. The crude product was purified
by column chromatography on silica (hexanes/EtOAc, 9:1) to afford
the title compound <bold>18</bold> as a pale yellow oil. Yield: 387
mg (92%); [&#x003b1;]<sup>20</sup><sub>D</sub> &#x02212;21 (<italic>c</italic> 0.08, MeOH); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x003b4;
6.51 (dd, <italic>J</italic> = 15.5, 10.9 Hz, 1H), 6.18 (ddd, <italic>J</italic> = 14.2, 10.3, 1.0 Hz, 1H), 5.75 (dd, <italic>J</italic> = 15.2, 5.9 Hz, 1H), 5.62&#x02013;5.31 (m, 5H), 4.47 (td, <italic>J</italic> = 6.6, 1.8 Hz, 1H), 4.21&#x02013;4.12 (m, 1H), 3.66 (t,
3H), 2.44 (t, <italic>J</italic> = 7.9 Hz, 2H), 2.30 (t, <italic>J</italic> = 7.6 Hz, 2H), 2.28&#x02013;2.15 (m, 2H), 2.11&#x02013;1.94 (m, 4H),
1.63 (q, <italic>J</italic> = 7.4 Hz, 2H), 1.40&#x02013;1.25 (m, 4H),
0.96 (t, <italic>J</italic> = 7.5 Hz, 3H), 0.91 (s, 9H), 0.89 (s,
9H), 0.12 (d, <italic>J</italic> = 8.3 Hz, 6H), 0.03 (d, <italic>J</italic> = 8.3 Hz, 6H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) &#x003b4;
174.3, 141.2, 139.3, 134.4, 131.9, 128.6, 125.4, 124.1, 110.7, 93.4,
83.6, 72.9, 63.7, 51.6, 36.8, 36.4, 34.2, 29.4, 29.0, 27.4, 26.0 (3C),
26.0 (3C), 25.0, 20.9, 18.5, 18.4, 14.4, &#x02212;4.3 (2C), &#x02212;4.6,
&#x02212;4.8; HRESTOFMS <italic>m</italic>/<italic>z</italic> 625.4084
[M<italic> + </italic>Na]<sup>+</sup> (calcd for C<sub>35</sub>H<sub>62</sub>O<sub>4</sub>Si<sub>2</sub>Na, 625.4085); TLC (hexanes/EtOAc,
9:1, CAM stain) <italic>R</italic><sub><italic>f</italic></sub> =
0.63.</p></sec><sec id="sec3.4"><title>Methyl (7<italic>Z</italic>,10<italic>R</italic>,11<italic>E</italic>,13<italic>E</italic>,17<italic>S</italic>,19<italic>Z</italic>)-10,17-Dihydroxydocosa-7,11,13,19-tetraen-15-ynoate
(<bold>19</bold>)</title><p>TBAF (704 mg, 2.70 mmol, 5.0 equiv, 1.0
M in THF) was added to a solution of TBS-protected alcohol <bold>18</bold> (325 mg, 0.54 mmol, 1.0 equiv) in THF (6.9 mL) at 0 &#x000b0;C. The
reaction was stirred for 2.5 h before it was quenched with phosphate
buffer (pH = 7.2, 2.8 mL). Brine (30 mL) and EtOAc (30 mL) were added,
and the phases were separated. The H<sub>2</sub>O phase was extracted
with EtOAc (2 &#x000d7; 30 mL) and the combined organic layers were dried
(Na<sub>2</sub>SO<sub>4</sub>) before the solvent was evaporated.
The crude product was purified by column chromatography on silica
(hexanes/EtOAc, 7:3) to afford the title compound <bold>19</bold> as
a pale yellow oil. Yield: 202 mg (85%); [&#x003b1;]<sup>20</sup><sub>D</sub> &#x02212;16 (<italic>c</italic> 0.06, MeOH); <sup>1</sup>H
NMR (400 MHz, CDCl<sub>3</sub>) &#x003b4; 6.55 (dd, <italic>J</italic> = 15.6, 11.0 Hz, 1H), 6.27 (dd, <italic>J</italic> = 14.9, 11.6
Hz, 1H), 5.81 (dd, <italic>J</italic> = 15.2, 6.1 Hz, 1H), 5.67&#x02013;5.49
(m, 3H), 5.48&#x02013;5.31 (m, 2H), 4.52 (td, <italic>J</italic> =
6.4, 1.9 Hz, 1H), 4.25&#x02013;4.16 (m, 1H), 3.68 (t, 3H), 2.49 (t, <italic>J</italic> = 6.9 Hz, 2H), 2.35&#x02013;2.26 (m, 4H), 2.14&#x02013;1.99
(m, 4H), 1.98 (d, <italic>J</italic> = 5.4 Hz, 1H), 1.71 (bs, 1H);
1.62 (p, <italic>J</italic> = 7.5 Hz, 2H), 1.43&#x02013;1.27 (m, 4H),
0.97 (t, <italic>J</italic> = 7.5 Hz, 3H); <sup>13</sup>C NMR (101
MHz, CDCl<sub>3</sub>) &#x003b4; 174.4, 141.5, 138.4, 136.1, 133.8,
129.4, 124.3, 122.9, 110.9, 92.6, 84.1, 71.7, 62.7, 51.7, 35.8, 35.5,
34.2, 29.3, 28.9, 27.4, 25.0, 21.0, 14.4; HRESTOFMS <italic>m</italic>/<italic>z</italic> 397.2354 [M <italic>+ </italic>Na]<sup>+</sup> (calcd for C<sub>23</sub>H<sub>34</sub>O<sub>4</sub>Na, 397.2355);
TLC (hexanes/EtOAc, 7:3, CAM stain) <italic>R</italic><sub><italic>f</italic></sub> = 0.26.</p></sec><sec id="sec3.5"><title>Methyl (7<italic>Z</italic>,10<italic>R</italic>,11<italic>E</italic>,13<italic>E</italic>,15<italic>Z</italic>,17<italic>S</italic>,19<italic>Z</italic>)-10,17-Dihydroxydocosa-7,11,13,15,19-pentaenoate
(<bold>6</bold>)</title><p>To a solution of alkyne <bold>19</bold> (30
mg,
0.08 mmol) in EtOAc/pyridine/1-octene (1.65 mL, 10:1:1) under argon)
was added Lindlar&#x02019;s catalyst (45 mg), and the flask was evacuated
and filled with argon. The reaction was stirred for 60 h at ambient
temperature under a balloon of hydrogen gas until completion. The
reaction mixture was loaded directly onto a silica gel column and
purified by chromatography (hexanes/EtOAc, 9:1) to afford the title
compound <bold>6</bold> as a pale yellow oil. Yield: 15 mg (50%).
[&#x003b1;]<sup>20</sup><sub>D</sub> = &#x02212;19 (<italic>c</italic> 0.08, MeOH); UV (MeOH) &#x003bb;<sub>max</sub> 262 (log &#x003b5; 4.52),
271 (log &#x003b5; 4.60) and 282 nm (log &#x003b5; 4.53); <sup>1</sup>H NMR (500 MHz, MeOH-<italic>d</italic><sub>4</sub>) and <sup>13</sup>C NMR (126 MHz, MeOH-<italic>d</italic><sub>4</sub>), see Table <xref rid="tbl1" ref-type="other">1</xref>; HRESTOFMS <italic>m</italic>/<italic>z</italic> 399.2511 [M <italic>+ </italic>Na]<sup>+</sup> (calcd for C<sub>23</sub>H<sub>36</sub>O<sub>4</sub>Na, 399.2506); TLC (hexanes/EtOAc,
6:4, CAM stain) <italic>R</italic><sub><italic>f</italic></sub> =
0.16; diastereomeric ratio was determined by HPLC (Eclipse XDB-C18,
MeOH/H<sub>2</sub>O, 8:2, 0.8 mL/min); <italic>t</italic><sub>r</sub>(minor) = 6.67 min and <italic>t</italic><sub>r</sub>(major) = 8.31
min.</p></sec><sec id="sec3.6"><title>Protectin D1<sub>n-3&#x000a0;DPA</sub> (<bold>5</bold>)</title><p>Methyl ester <bold>6</bold> (14 mg, 0.04 mmol) was dissolved in
MeOH/H<sub>2</sub>O, 1:1 (35 mL), and cooled to 0 &#x000b0;C. LiOH (1.0
M, 2.2 mL) was added dropwise. The reaction mixture was stirred at
the above-mentioned temperature for 48 h, after which a saturated
solution of NaH<sub>2</sub>PO<sub>4</sub> (3.3 mL) was added. Next,
NaCl (10.0 g) was added followed by EtOAc (50 mL). The organic phase
was decanted, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated
in vacuo, affording the title compound <bold>5</bold> as a colorless
oil. Yield: 9.5 mg (71%); [&#x003b1;]<sup>20</sup><sub>D</sub> &#x02212;28
(<italic>c</italic> 0.1, MeOH); UV (MeOH) &#x003bb;<sub>max</sub> 262
(log &#x003b5; 4.53), 271 (log &#x003b5; 4.60), 282 nm (log &#x003b5; 4.54); <sup>1</sup>H NMR (400 MHz, MeOH-<italic>d</italic><sub>4</sub>) &#x003b4;
6.52 (dd, <italic>J</italic> = 13.7, 11.1 Hz, 1H), 6.31&#x02013;6.20
(m, 2H), 6.08 (t, <italic>J</italic> = 11.0 Hz, 1H), 5.74 (dd, <italic>J</italic> = 14.5, 6.6 Hz, 1H), 5.50&#x02013;5.30 (m, 5H), 4.56 (dt, <italic>J</italic> = 8.6, 6.3 Hz, 1H), 4.15&#x02013;4.09 (m, 1H), 2.40&#x02013;2.17
(m, 6H), 2.10&#x02013;2.02 (m, 4H), 1.60 (p, <italic>J</italic> = 7.4
Hz, 2H), 1.42&#x02013;1.30 (m, 4H), 0.97 (t, <italic>J</italic> = 7.5
Hz, 3H); <sup>13</sup>C NMR (101 MHz, MeOH-<italic>d</italic><sub>4</sub>) &#x003b4; 178.2, 138.0, 134.9, 134.8, 134.7, 132.9, 131.3,
130.6, 128.9, 126.2, 125.3, 73.1, 68.6, 36.4, 36.4, 35.4, 30.4, 29.9,
28.3, 26.2, 21.7, 14.6; HRESTOFMS <italic>m</italic>/<italic>z</italic> 361.2378 [M<italic> &#x02013; </italic>H]<sup>+</sup> (calcd for
C<sub>22</sub>H<sub>33</sub>O<sub>4</sub> 361.2385); TLC (Et<sub>2</sub>O with a drop of AcOH, CAM stain) <italic>R</italic><sub><italic>f</italic></sub> = 0.34. The purity (&#x0003e;98%) was determined by HPLC
analysis (Eclipse XDB-C18, MeOH/3.3 mM HCOOH in H<sub>2</sub>O, 7:3,
1.0 mL/min); <italic>t</italic><sub>r</sub>(major) = 9.52 min and <italic>t</italic><sub>r</sub>(minor) = 13.49 min.</p></sec><sec id="sec3.7"><title>Biogenic Synthesis and
Identification of 16,17-Epoxy PD<sub>n-3&#x000a0;DPA</sub></title><p>In brief, soybean lipoxygenase
(50 U/100 mL) was incubated with n-3 DPA (0.2 &#x003bc;M in 200 &#x003bc;L
of borate buffer (pH = 8.2)) at 4 &#x000b0;C. After 20 s, eight volumes
of acidified MeOH (apparent pH &#x0223c;3.5) were added. The resulting
products were investigated by target lipid mediator metabololipidomics
as previously described.<sup><xref ref-type="bibr" rid="ref32">32</xref></sup></p></sec><sec id="sec3.8"><title>Lipid Mediator
Metabololipidomics</title><p>Matching of synthetic <bold>5</bold> with
endogenous products was conducted as previously reported.<sup><xref ref-type="bibr" rid="ref31">31</xref></sup> Briefly, as developed for other lipid mediators,
all samples for LC-MS/MS-based lipidomics were subject to solid-phase
extraction. Prior to sample extraction, <italic>d</italic><sub>4</sub>-LTB<sub>4</sub> (500 pg) was added. Extracted samples were analyzed
with an LC-MS system, a QTrap 5500 (ABSciex) equipped with a Shimadzu
SIL-20AC HT autosampler and LC-20AD LC pumps. An Agilent Eclipse Plus
C18 column (100 mm &#x000d7; 4.6 mm &#x000d7; 1.8 &#x003bc;m) was used with
a gradient of MeOH/H<sub>2</sub>O/acetic acid of 55:45:0.01 (v/v/v)
to 100:0:0.01 at a 0.4 mL/min flow rate. To monitor targeted SPMs,
we used multiple reaction monitoring (MRM) with signature ion fragments
for each molecule (at least six diagnostic ions).<sup><xref ref-type="bibr" rid="ref32">32</xref></sup> GC-MS analyses were carried out as previously reported.<sup><xref ref-type="bibr" rid="ref9">9</xref></sup></p></sec><sec id="sec3.9"><title>Preparation of Naturally Occurring PD1<sub>n-3&#x000a0;DPA</sub> (<bold>5</bold>)</title><p>Male FVB mice
(6 to 8 weeks old) purchased
from Charles River Laboratories were fed ad libitum laboratory rodent
diet 20-5058 (Lab Diet, Purina Mills). All animal experimental procedures
were approved by the Standing Committee on Animals of Harvard Medical
School (protocol no. 02570) and complied with institutional and U.S.
National Institutes of Health (NIH) guidelines. Peritonitis was induced
by zymosan injection (1 mg/mL) intraperitoneally (ip), and exudates
were obtained 4 h later. Human macrophages were prepared from peripheral
blood mononuclear cells following literature protocols.<sup><xref ref-type="bibr" rid="ref31">31</xref></sup> Macrophages were suspended in DPBS<sup>+/+</sup> (5 &#x000d7; 10<sup>7</sup> cells/mL) and incubated with n-3 DPA (1
&#x003bc;M) and 0.1 mg of serum-treated zymosan (37 &#x000b0;C, 30 min,
pH = 7.45). The incubations were stopped with 2 mL of ice-cold MeOH,
and mediators extracted over C18 columns as described above.</p></sec><sec id="sec3.10"><title>Anti-inflammatory
and Pro-resolving Actions</title><p>Mice were
administered intravenously (iv) vehicle (saline containing 0.1% EtOH),
PD1<sub>n-3&#x000a0;DPA</sub> (<bold>5</bold>) (10 ng/mouse),
or protectin D1 (<bold>3</bold>) for the purpose of direct comparison
(10 ng/mouse) 5 min prior to ip zymosan administration (1 mg). After
4 h the exudates were collected and the number of extravasated neutrophils
was determined using Turks solution and flow cytometry.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> Human macrophages and peripheral blood neutrophils
were prepared; then phagocytosis and efferocytosis were assessed as
described in ref (<xref ref-type="bibr" rid="ref19">19</xref>). Briefly, cells were incubated with vehicle (0.1% EtOH in DPBS),
PD1<sub>n3&#x000a0;DPA</sub> (<bold>5</bold>), or protectin D1 (<bold>5</bold>) at the indicated concentrations for 15 min at 37 &#x000b0;C;
then FITC-labeled zymosan- or bisbenzimide-labeled apoptotic neutrophils
were added and cells incubated for 60 min at 37 &#x000b0;C. Phagocytosis
was assessed using an M3 SpectraMax plate reader.</p></sec></sec></body><back><notes id="notes-2" notes-type="si"><title>Supporting Information Available</title><p>Experimental procedures and
characterization data of synthetic intermediates <bold>7</bold>&#x02013;<bold>19</bold>, PD1<sub>n-3&#x000a0;DPA</sub> (<bold>5</bold>), and
its methyl ester <bold>6</bold>, <sup>1</sup>H, <sup>13</sup>C, and
2D-NMR spectra data, HRMS and UV/vis spectra, HPLC analyses of synthetic
compounds as well as LC/MS/MS data and GC/MS chromatograms of endogenous
PD1<sub>n-3DPA</sub> (<bold>5</bold>) and its bis-TMS ether
of methyl ester <bold>6</bold> are available free of charge via the
Internet at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://pubs.acs.org">http://pubs.acs.org</uri>.</p></notes><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sifile1"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="np4009865_si_001.pdf"><caption><p>np4009865_si_001.pdf</p></caption></media></supplementary-material></sec><notes id="notes-3"><title>Author Present Address</title><p><sup>&#x000a7;</sup> On leave from the Department of Pharmaceutical Chemistry,
School
of Pharmacy, University of Oslo.</p></notes><notes id="notes-4"><title>Author Contributions</title><p>The manuscript
was written through contributions of all authors. All authors have
given approval to the final version of the manuscript.</p></notes><notes id="notes-5" notes-type="conflict-of-interest"><p>The authors
declare the following competing financial interest(s): J.D. and C.N.S.
have filed patents on PD1<sub>n-3&#x000a0;DPA</sub> (<bold>5</bold>) and related compounds. C.N.S.&#x02019;s interests are reviewed and
are managed by BWH and Partners HealthCare in accordance with their
conflict of interest policies.</p></notes><ack><title>Acknowledgments</title><p>We are indebted
to Dr. P. P. Molesworth, Department of Chemistry,
University of Oslo, for skillful technical assistance with acquisition
of 2D-NMR spectra. The Norwegian Research Council (KOSK II) and the
School of Pharmacy, University of Oslo, are gratefully acknowledged
for Ph.D. scholarships to M.A. and J.E.T., respectively. T.V.H. is
grateful for a Leiv Eriksson travel grant from The Norwegian Research
Council. J.D., R.C., and C.Y.C. are supported by the National Institutes
of Health GM Grant PO1GM095467 (C.N.S.).</p></ack><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal" id="cit1"><name><surname>Tabas</surname><given-names>I.</given-names></name>; <name><surname>Glass</surname><given-names>C. K.</given-names></name>
<source>Science</source>
<year>2013</year>, <volume>339</volume>, <fpage>166</fpage>&#x02013;<lpage>172</lpage>.<pub-id pub-id-type="pmid">23307734</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="book" id="cit2"><person-group person-group-type="allauthors"><name><surname>Majno</surname><given-names>G.</given-names></name>; <name><surname>Joris</surname><given-names>I.</given-names></name></person-group><source>Cells, Tissues and Disease. Principles
of General Pathology</source>; <publisher-name>Blackwell Science</publisher-name>: <publisher-loc>Cambridge</publisher-loc>, <year>2004</year>; pp <fpage>307</fpage>&#x02013;<lpage>382</lpage>.</mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="book" id="cit3"><person-group person-group-type="allauthors"><name><surname>Ward</surname><given-names>P. A.</given-names></name></person-group><article-title>Acute and Chronic
Inflammation</article-title>. In <source>Fundamentals of Inflammation</source>; <person-group person-group-type="editor"><name><surname>Serhan</surname><given-names>C. N.</given-names></name>; <name><surname>Ward</surname><given-names>P. A.</given-names></name>; <name><surname>Gilroy</surname><given-names>D. W.</given-names></name></person-group>, Eds.; <publisher-name>Cambridge University Press</publisher-name>: <publisher-loc>Cambridge</publisher-loc>, <year>2010</year>; pp <fpage>1</fpage>&#x02013;<lpage>16</lpage>.</mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name><surname>Serhan</surname><given-names>C. N.</given-names></name>; <name><surname>Savill</surname><given-names>J.</given-names></name>
<source>Nat. J. Immunol.</source>
<year>2005</year>, <volume>6</volume>, <fpage>1191</fpage>&#x02013;<lpage>1197</lpage>.</mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name><surname>Serhan</surname><given-names>C. N.</given-names></name>; <name><surname>Gotlinger</surname><given-names>K.</given-names></name>; <name><surname>Hong</surname><given-names>S.</given-names></name>; <name><surname>Arita</surname><given-names>M.</given-names></name>
<source>Prostaglandins Other Lipid
Mediators</source>
<year>2004</year>, <volume>73</volume>, <fpage>155</fpage>&#x02013;<lpage>172</lpage>.<pub-id pub-id-type="pmid">15290791</pub-id></mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name><surname>Serhan</surname><given-names>C. N.</given-names></name>
<source>Annu. Rev. Immunol.</source>
<year>2007</year>, <volume>25</volume>, <fpage>101</fpage>&#x02013;<lpage>137</lpage>.<pub-id pub-id-type="pmid">17090225</pub-id></mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><name><surname>Serhan</surname><given-names>C. N.</given-names></name>; <name><surname>Chiang</surname><given-names>N.</given-names></name>
<source>Br. J. Pharmacol.</source>
<year>2008</year>, <volume>153</volume>, <fpage>S200</fpage>&#x02013;<lpage>S215</lpage>.<pub-id pub-id-type="pmid">17965751</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name><surname>Serhan</surname><given-names>C. N.</given-names></name>; <name><surname>Clish</surname><given-names>C. B.</given-names></name>; <name><surname>Brannon</surname><given-names>J.</given-names></name>; <name><surname>Colgan</surname><given-names>S. P.</given-names></name>; <name><surname>Chiang</surname><given-names>N.</given-names></name>; <name><surname>Gronert</surname><given-names>K.</given-names></name>
<source>J. Exp. Med.</source>
<year>2000</year>, <volume>192</volume>, <fpage>1197</fpage>&#x02013;<lpage>1204</lpage>.<pub-id pub-id-type="pmid">11034610</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name><surname>Serhan</surname><given-names>C. N.</given-names></name>; <name><surname>Hong</surname><given-names>S.</given-names></name>; <name><surname>Gronert</surname><given-names>K.</given-names></name>; <name><surname>Colgan</surname><given-names>S. P.</given-names></name>; <name><surname>Devchand</surname><given-names>P. R.</given-names></name>; <name><surname>Mirick</surname><given-names>G.</given-names></name>; <name><surname>Moussignac</surname><given-names>R. L.</given-names></name>
<source>J. Exp. Med.</source>
<year>2002</year>, <volume>196</volume>, <fpage>1025</fpage>&#x02013;<lpage>1037</lpage>.<pub-id pub-id-type="pmid">12391014</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name><surname>Hong</surname><given-names>S.</given-names></name>; <name><surname>Gronert</surname><given-names>K.</given-names></name>; <name><surname>Devchand</surname><given-names>P. R.</given-names></name>; <name><surname>Moussignac</surname><given-names>R.-L.</given-names></name>; <name><surname>Serhan</surname><given-names>C. N.</given-names></name>
<source>J. Biol. Chem.</source>
<year>2003</year>, <volume>278</volume>, <fpage>14677</fpage>&#x02013;<lpage>14687</lpage>.<pub-id pub-id-type="pmid">12590139</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name><surname>Mukherjee</surname><given-names>P. K.</given-names></name>; <name><surname>Marcheselli</surname><given-names>V. L.</given-names></name>; <name><surname>Serhan</surname><given-names>C. N.</given-names></name>; <name><surname>Bazan</surname><given-names>N. G.</given-names></name>
<source>Proc. Natl. Acad. Sci.
U.S.A.</source>
<year>2004</year>, <volume>101</volume>, <fpage>8491</fpage>&#x02013;<lpage>8496</lpage>.<pub-id pub-id-type="pmid">15152078</pub-id></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name><surname>Ariel</surname><given-names>A.</given-names></name>; <name><surname>Pin-Lan</surname><given-names>L.</given-names></name>; <name><surname>Wang</surname><given-names>W.</given-names></name>; <name><surname>Tang</surname><given-names>W. X.</given-names></name>; <name><surname>Fredman</surname><given-names>G.</given-names></name>; <name><surname>Hong</surname><given-names>S.</given-names></name>; <name><surname>Gotlinger</surname><given-names>K. H.</given-names></name>; <name><surname>Serhan</surname><given-names>C. N.</given-names></name>
<source>J. Biol. Chem.</source>
<year>2005</year>, <volume>280</volume>, <fpage>43079</fpage>&#x02013;<lpage>43086</lpage>.<pub-id pub-id-type="pmid">16216871</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name><surname>Serhan</surname><given-names>C. N.</given-names></name>; <name><surname>Yang</surname><given-names>R.</given-names></name>; <name><surname>Martinod</surname><given-names>K.</given-names></name>; <name><surname>Kasuga</surname><given-names>K.</given-names></name>; <name><surname>Pillai</surname><given-names>P. S.</given-names></name>; <name><surname>Porter</surname><given-names>T. F.</given-names></name>; <name><surname>Oh</surname><given-names>S. F.</given-names></name>; <name><surname>Spite</surname><given-names>M.</given-names></name>
<source>J. Exp. Med.</source>
<year>2009</year>, <volume>206</volume>, <fpage>15</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">19103881</pub-id></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name><surname>Serhan</surname><given-names>C. N.</given-names></name>; <name><surname>Chiang</surname><given-names>N.</given-names></name>
<source>Curr. Opin. Pharmacol.</source>
<year>2013</year>, <volume>13</volume>, <fpage>632</fpage>&#x02013;<lpage>640</lpage>.<pub-id pub-id-type="pmid">23747022</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name><surname>Serhan</surname><given-names>C. N.</given-names></name>; <name><surname>Petasis</surname><given-names>N. A.</given-names></name>
<source>Chem. Rev.</source>
<year>2011</year>, <volume>111</volume>, <fpage>5922</fpage>&#x02013;<lpage>5943</lpage><comment>and references therein</comment>.<pub-id pub-id-type="pmid">21766791</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name><surname>Lemaitre</surname><given-names>R. N.</given-names></name>; <name><surname>Tanaka</surname><given-names>T.</given-names></name>; <name><surname>Tang</surname><given-names>W.</given-names></name>; <name><surname>Manichaikul</surname><given-names>A.</given-names></name>; <name><surname>Foy</surname><given-names>M.</given-names></name>; <name><surname>Kabagambe</surname><given-names>E. K.</given-names></name>; <name><surname>Nettleton</surname><given-names>J. A.</given-names></name>; <name><surname>King</surname><given-names>I. A.</given-names></name>; <name><surname>Weng</surname><given-names>L.-C.</given-names></name>; <name><surname>Bhattacharya</surname><given-names>S.</given-names></name>; <name><surname>Bandinelli</surname><given-names>S.</given-names></name>; <name><surname>Bis</surname><given-names>J. C.</given-names></name>; <name><surname>Rich</surname><given-names>S. S.</given-names></name>; <name><surname>Jacobs</surname><given-names>D. R.</given-names><suffix>Jr.</suffix></name>; <name><surname>Cherubini</surname><given-names>A.</given-names></name>; <name><surname>McKnight</surname><given-names>B.</given-names></name>; <name><surname>Liang</surname><given-names>S.</given-names></name>; <name><surname>Gu5</surname><given-names>X.</given-names></name>; <name><surname>Rice</surname><given-names>K.</given-names></name>; <name><surname>Laurie</surname><given-names>C. C.</given-names></name>; <name><surname>Lumley</surname><given-names>T.</given-names></name>; <name><surname>Browning</surname><given-names>B. L.</given-names></name>; <name><surname>Psaty</surname><given-names>B. M.</given-names></name>; <name><surname>Chen</surname><given-names>Y.-D. I.</given-names></name>; <name><surname>Friedlander</surname><given-names>Y.</given-names></name>; <name><surname>Djousse</surname><given-names>L.</given-names></name>; <name><surname>Wu</surname><given-names>J. H. Y.</given-names></name>; <name><surname>Siscovick</surname><given-names>D. S.</given-names></name>; <name><surname>Uitterlinden</surname><given-names>A. G.</given-names></name>; <name><surname>Arnett</surname><given-names>D. K.</given-names></name>; <name><surname>Ferrucci</surname><given-names>L.</given-names></name>; <name><surname>Fornage</surname><given-names>M.</given-names></name>; <name><surname>Tsai</surname><given-names>M. Y.</given-names></name>; <name><surname>Mozaffarian</surname><given-names>D.</given-names></name>; <name><surname>Steffen</surname><given-names>L. M.</given-names></name>
<source>PLoS Genet.</source>
<year>2011</year>, <volume>7</volume>, <fpage>e1002193</fpage>.<pub-id pub-id-type="pmid">21829377</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name><surname>Kaur</surname><given-names>G.</given-names></name>; <name><surname>Cameron-Smith</surname><given-names>D.</given-names></name>; <name><surname>Garg</surname><given-names>M.</given-names></name>; <name><surname>Sinclair</surname><given-names>A. J.</given-names></name>
<source>Prog. Lipid Res.</source>
<year>2011</year>, <volume>50</volume>, <fpage>28</fpage>&#x02013;<lpage>34</lpage><comment>and
references therein</comment>.<pub-id pub-id-type="pmid">20655949</pub-id></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><name><surname>Hussein</surname><given-names>N.</given-names></name>; <name><surname>Fedorova</surname><given-names>I.</given-names></name>; <name><surname>Moriguchi</surname><given-names>T.</given-names></name>; <name><surname>Hamazaki</surname><given-names>K.</given-names></name>; <name><surname>Kim</surname><given-names>H.-Y.</given-names></name>; <name><surname>Hoshiba</surname><given-names>J.</given-names></name>; <name><surname>Salem</surname><given-names>N.</given-names><suffix>Jr.</suffix></name>
<source>Lipids</source>
<year>2009</year>, <volume>44</volume>, <fpage>685</fpage>&#x02013;<lpage>702</lpage>.<pub-id pub-id-type="pmid">19588181</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name><surname>Dalli</surname><given-names>J.</given-names></name>; <name><surname>Colas</surname><given-names>R. A.</given-names></name>; <name><surname>Serhan</surname><given-names>C. N.</given-names></name>
<source>Sci. Rep.</source>
<year>2013</year>, <volume>3</volume>, <fpage>1940</fpage>.<pub-id pub-id-type="pmid">23736886</pub-id></mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name><surname>Serhan</surname><given-names>C. N.</given-names></name>; <name><surname>Gotlinger</surname><given-names>K.</given-names></name>; <name><surname>Hong</surname><given-names>S.</given-names></name>; <name><surname>Lu</surname><given-names>Y.</given-names></name>; <name><surname>Siegelman</surname><given-names>J.</given-names></name>; <name><surname>Baer</surname><given-names>T.</given-names></name>; <name><surname>Yang</surname><given-names>R.</given-names></name>; <name><surname>Colgan</surname><given-names>S. P.</given-names></name>; <name><surname>Petasis</surname><given-names>N. A.</given-names></name>
<source>J. Immunol.</source>
<year>2006</year>, <volume>176</volume>, <fpage>1848</fpage>&#x02013;<lpage>1859</lpage>.<pub-id pub-id-type="pmid">16424216</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal" id="cit21"><name><surname>Crawford</surname><given-names>M. A.</given-names></name>; <name><surname>Broadhurst</surname><given-names>C. L.</given-names></name>; <name><surname>Guest</surname><given-names>M.</given-names></name>; <name><surname>Nagar</surname><given-names>A.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Ghebremeskel</surname><given-names>K. A.</given-names></name>; <name><surname>Schmidt</surname><given-names>W.</given-names></name>
<source>Prostaglandins Leukot. Essent. Fatty Acids</source>
<year>2013</year>, <volume>88</volume>, <fpage>5</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="pmid">23206328</pub-id></mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name><surname>Jakobsen</surname><given-names>M. G.</given-names></name>; <name><surname>Vik</surname><given-names>A.</given-names></name>; <name><surname>Hansen</surname><given-names>T. V.</given-names></name>
<source>Tetrahedron Lett.</source>
<year>2012</year>, <volume>53</volume>, <fpage>5837</fpage>&#x02013;<lpage>5839</lpage>.</mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal" id="cit23"><name><surname>Krow</surname><given-names>G. R.</given-names></name>
<source>Org. React.</source>
<year>1993</year>, <volume>43</volume>, <fpage>251</fpage>&#x02013;<lpage>265</lpage>.</mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal" id="cit24"><name><surname>Tello-Aburto</surname><given-names>R.</given-names></name>; <name><surname>Ochoa-Teran</surname><given-names>A.</given-names></name>; <name><surname>Olivo</surname><given-names>H. F.</given-names></name>
<source>Tetrahedron Lett.</source>
<year>2006</year>, <volume>47</volume>, <fpage>5915</fpage>&#x02013;<lpage>5917</lpage>.</mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal" id="cit25"><name><surname>Nicolaou</surname><given-names>K. C.</given-names></name>; <name><surname>Webber</surname><given-names>S. E.</given-names></name>; <name><surname>Ramphal</surname><given-names>J.</given-names></name>; <name><surname>Abe</surname><given-names>Y.</given-names></name>
<source>Angew. Chem.</source>
<year>1987</year>, <volume>99</volume>, <fpage>1077</fpage>&#x02013;<lpage>1079</lpage>.</mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal" id="cit26"><name><surname>Sonogashira</surname><given-names>K.</given-names></name>; <name><surname>Tohda</surname><given-names>Y.</given-names></name>; <name><surname>Hagihara</surname><given-names>N.</given-names></name>
<source>Tetrahedron Lett.</source>
<year>1975</year>, <volume>16</volume>, <fpage>4467</fpage>&#x02013;<lpage>4470</lpage>.</mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal" id="cit27"><name><surname>Corey</surname><given-names>E. J.</given-names></name>; <name><surname>Snider</surname><given-names>B. B.</given-names></name>
<source>J. Am. Chem. Soc.</source>
<year>1972</year>, <volume>94</volume>, <fpage>6190</fpage>&#x02013;<lpage>6192</lpage>.</mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal" id="cit28"><name><surname>Nicolaou</surname><given-names>K. C.</given-names></name>; <name><surname>Ladduwahetty</surname><given-names>T.</given-names></name>; <name><surname>Taffer</surname><given-names>I. M.</given-names></name>; <name><surname>Zipkin</surname><given-names>R. E.</given-names></name>
<source>Synthesis</source>
<year>1986</year>, <fpage>344</fpage>&#x02013;<lpage>347</lpage>.</mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal" id="cit29"><name><surname>Aursnes</surname><given-names>M.</given-names></name>; <name><surname>Tungen</surname><given-names>J. T.</given-names></name>; <name><surname>Vik</surname><given-names>A.</given-names></name>; <name><surname>Dalli</surname><given-names>J.</given-names></name>; <name><surname>Hansen</surname><given-names>T. V.</given-names></name>
<source>Org. Biomol. Chem.</source>
<year>2014</year>, <volume>12</volume>, <fpage>432</fpage>&#x02013;<lpage>437</lpage>.<pub-id pub-id-type="pmid">24253202</pub-id></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal" id="cit30"><name><surname>Duffield</surname><given-names>J. S.</given-names></name>; <name><surname>Hong</surname><given-names>S.</given-names></name>; <name><surname>Vaidya</surname><given-names>V. S.</given-names></name>; <name><surname>Lu</surname><given-names>Y.</given-names></name>; <name><surname>Fredman</surname><given-names>G.</given-names></name>; <name><surname>Serhan</surname><given-names>C. N.</given-names></name>; <name><surname>Bonventre</surname><given-names>J. V.</given-names></name>
<source>J. Immunol.</source>
<year>2006</year>, <volume>177</volume>, <fpage>5902</fpage>&#x02013;<lpage>5911</lpage>.<pub-id pub-id-type="pmid">17056514</pub-id></mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal" id="cit31"><name><surname>Dalli</surname><given-names>J.</given-names></name>; <name><surname>Winkler</surname><given-names>W.</given-names></name>; <name><surname>Colas</surname><given-names>R. A.</given-names></name>; <name><surname>Arnardottir</surname><given-names>H.</given-names></name>; <name><surname>Cheng</surname><given-names>C. Y.</given-names></name>; <name><surname>Chiang</surname><given-names>N.</given-names></name>; <name><surname>Petasis</surname><given-names>N. A.</given-names></name>; <name><surname>Serhan</surname><given-names>C. N.</given-names></name>
<source>Chem. Biol.</source>
<year>2013</year>, <volume>20</volume>, <fpage>188</fpage>&#x02013;<lpage>201</lpage>.<pub-id pub-id-type="pmid">23438748</pub-id></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal" id="cit32"><name><surname>Dalli</surname><given-names>J.</given-names></name>; <name><surname>Serhan</surname><given-names>C. N.</given-names></name>
<source>Blood</source>
<year>2012</year>, <volume>120</volume>, <fpage>e60</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">22904297</pub-id></mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal" id="cit33"><name><surname>Corey</surname><given-names>E. J.</given-names></name>; <name><surname>Mehrota</surname><given-names>M. M.</given-names></name>
<source>Tetrahedron Lett.</source>
<year>1986</year>, <volume>27</volume>, <fpage>5173</fpage>&#x02013;<lpage>5176</lpage>.</mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal" id="cit34"><name><surname>Serhan</surname><given-names>C. N.</given-names></name>
<source>Biochim. Biophys.
Acta</source>
<year>1994</year>, <volume>1212</volume>, <fpage>1</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="pmid">8155718</pub-id></mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal" id="cit35"><name><surname>Xu</surname><given-names>Z.-Z.</given-names></name>; <name><surname>Liu</surname><given-names>X.-J.</given-names></name>; <name><surname>Berta</surname><given-names>T.</given-names></name>; <name><surname>Park</surname><given-names>C.-K.</given-names></name>; <name><surname>L&#x000fc;</surname><given-names>N.</given-names></name>; <name><surname>Serhan</surname><given-names>C. N.</given-names></name>; <name><surname>Ji</surname><given-names>R.-R.</given-names></name>
<source>Ann. Neurol.</source>
<year>2013</year>, <volume>74</volume>, <fpage>490</fpage>&#x02013;<lpage>495</lpage>.<pub-id pub-id-type="pmid">23686636</pub-id></mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal" id="cit36"><name><surname>Wernerova</surname><given-names>M.</given-names></name>; <name><surname>Hudlicky</surname><given-names>T.</given-names></name>
<source>Synlett</source>
<year>2010</year>, <volume>18</volume>, <fpage>2701</fpage>&#x02013;<lpage>2707</lpage>.</mixed-citation></ref></ref-list></back></article>
